CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

Home・Aandelen Lijst・Ocugen Inc

Ocugen Inc

Gesloten

1.35 4.65

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.3

Max

1.3599999999999999

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.5M -19M
Verkoop	1.7M 1.5M
EPS	-0.06
Winstmarge	-1,250.946
Werknemers	116
EBITDA	-987K -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+790% upside

Dividenden
By Dow Jones
Volgende Winsten	31 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-173M 454M
Vorige openingsprijs	-3.3
Vorige sluitingsprijs	1.35

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

0.6818 / 0.74 Steun & Weerstand

Ocugen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mei 2026, 22:52 UTC

Belangrijke Marktbewegers

Osisko Shares Fall on Planned Convertible Notes Offering

20 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mei 2026, 23:44 UTC

Winsten

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mei 2026, 23:35 UTC

Marktinformatie

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mei 2026, 23:30 UTC

Marktinformatie

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mei 2026, 23:15 UTC

Marktinformatie

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mei 2026, 23:14 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mei 2026, 23:02 UTC

Marktinformatie

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 22:27 UTC

Marktinformatie

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mei 2026, 22:14 UTC

Marktinformatie

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mei 2026, 22:10 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mei 2026, 22:00 UTC

Winsten

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mei 2026, 21:38 UTC

Winsten

Acquisities, Fusies, Overnames

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mei 2026, 21:27 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mei 2026, 21:20 UTC

Winsten

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mei 2026, 21:19 UTC

Winsten

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mei 2026, 21:18 UTC

Winsten

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mei 2026, 21:17 UTC

Winsten

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mei 2026, 21:16 UTC

Winsten

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Vergelijking

Prijswijziging

Ocugen Inc Prognose

Koersdoel

By TipRanks

790% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.57 USD 790%

Hoogste 22 USD

Laagste 7 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocugen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ocugen Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.6818 / 0.74Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.